Skip to main content

Table 4 Multivariable Generalized Estimating Equation (GEE) models of a gap of 12 months between laboratory measurements

From: Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study

  Liver (AST/ALT) Renal (Creatinine) Metabolic (Lipids)
(N = 3343) (N = 2955) (N = 2838)
Odds ratio 95 % CI p-value Odds ratio 95 % CI p-value Odds ratio 95 % CI p-value
Province
  British Columbia Ref    Ref    Ref   
  Ontario 1.03 (0.82,1.30) 0.79 0.95 (0.71,1.28) 0.74 2.78 (2.16,3.58) <0.0001
  Quebec 0.99 (0.74,1.32) 0.94 1.18 (0.86,1.61) 0.31 2.56 (1.96,3.33) <0.0001
Age at cART initiation (per 10 years) 0.77 (0.70,0.84) <0.0001 0.73 (0.66,0.81) <0.0001 0.87 (0.80,0.96) <0.01
Male 0.92 (0.74,1.15) 0.46 0.97 (0.74,1.28) 0.84 0.77 (0.63,0.94) 0.01
Race
  Caucasian Ref    Ref    Ref   
  Black 1.43 (1.05,1.96) 0.02 1.09 (0.69,1.73) 0.71 1.78 (1.29,2.45) <0.001
  Aboriginal 1.09 (0.73,1.64) 0.66 0.80 (0.48,1.33) 0.38 1.22 (0.75,1.96) 0.42
  Other 0.52 (0.35,0.75) <0.001 0.55 (0.35,0.85) <0.01 0.92 (0.65,1.30) 0.62
  Unknown 1.18 (0.92,1.52) 0.19 0.90 (0.69,1.18) 0.44 1.10 (0.90,1.35) 0.36
HCV and IDU status
  HCV- non-IDU Ref    Ref    Ref   
  HCV+ non-IDU 0.98 (0.67,1.43) 0.92 0.83 (0.52,1.33) 0.44 0.72 (0.50,1.03) 0.07
  HCV- IDU 1.02 (0.65,1.60) 0.92 1.04 (0.59,1.82) 0.89 0.86 (0.51,1.45) 0.58
  HCV+ IDU 2.21 (1.73,2.82) <0.0001 1.88 (1.40,2.53) <0.0001 1.70 (1.30,2.23) <0.001
  Unknown 1.15 (0.88,1.49) 0.30 1.47 (1.12,1.93) 0.01 0.55 (0.44,0.68) <0.0001
Grade 3 or 4 elevation at previous visit 0.64 (0.44,0.93) 0.02 1.74 (0.51,5.96) 0.38 0.68 (0.54,0.86) <0.01
VL < 50 copies/mL at gap start 0.67 (0.59,0.77) <0.0001 0.63 (0.52,0.75) <0.0001 0.82 (0.72,0.93) <0.01
CD4 count at gap start
  <200 cells/mm3 Ref    Ref    Ref   
  200-350 cells/mm3 0.92 (0.77,1.10) 0.35 1.07 (0.85,1.35) 0.55 1.02 (0.87,1.20) 0.80
  350-500 cells/mm3 0.88 (0.72,1.07) 0.18 1.08 (0.83,1.39) 0.58 1.11 (0.93,1.33) 0.26
  >500 cells/mm3 1.03 (0.84,1.26) 0.76 1.26 (0.97,1.63) 0.09 1.12 (0.93,1.35) 0.23
cART initiation year
  2000 Ref    Ref    Ref   
  2001-2005 0.56 (0.45,0.70) <0.0001 0.58 (0.44,0.77) 0.0001 0.83 (0.64,1.08) 0.16
  >2005 0.37 (0.29,0.48) <0.0001 0.39 (0.28,0.54) <0.0001 0.72 (0.55,0.94) 0.02
  1. IDU injection drug use as risk factor for HIV acquisition, HCV+ positive for Hepatitis C, VL viral load